I think that's what we see happening in Europe right now. We're all watching Wallonia, and we're curious to see what changes they've made in this latest development. Certainly, I think we support some effort to improve the system, if not take it out of agreements, as India has.
Ms. Murray, we've had a lot of testimony before this committee on the impact on Canadians of the patent extensions for drugs. We had as a witness Dr. Carolyn Pullen, the director of policy advocacy and strategy for the Canadian Nurses Association. She said that, under TPP, “the cost of drugs would increase, and implementing a national prescription drug program...would be less feasible”.
If drug costs were to increase, I'm wondering how this increase would affect health insurance claims and premiums in Canada.